Thomas Stauffer Larsen

3.9k total citations
146 papers, 2.1k citations indexed

About

Thomas Stauffer Larsen is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Thomas Stauffer Larsen has authored 146 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Genetics, 63 papers in Pathology and Forensic Medicine and 39 papers in Oncology. Recurrent topics in Thomas Stauffer Larsen's work include Lymphoma Diagnosis and Treatment (63 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (53 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Thomas Stauffer Larsen is often cited by papers focused on Lymphoma Diagnosis and Treatment (63 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (53 papers) and Chronic Lymphocytic Leukemia Research (25 papers). Thomas Stauffer Larsen collaborates with scholars based in Denmark, Sweden and United States. Thomas Stauffer Larsen's co-authors include Hans Carl Hasselbalch, Niels Pallisgaard, Ole Weis Bjerrum, Caroline Hasselbalch Riley, Vibe Skov, Michael Møller, Mads Thomassen, Torben A. Kruse, Morten K. Jensen and Lasse Kjær and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Thomas Stauffer Larsen

135 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Stauffer Larsen Denmark 25 1.4k 910 811 743 380 146 2.1k
Donna L. Forrest Canada 27 737 0.5× 1.4k 1.5× 422 0.5× 310 0.4× 392 1.0× 110 2.3k
David Joske Australia 20 809 0.6× 906 1.0× 741 0.9× 489 0.7× 774 2.0× 45 2.6k
Markus Pfirrmann Germany 22 1.7k 1.3× 1.9k 2.1× 222 0.3× 967 1.3× 264 0.7× 71 2.5k
Tariq I. Mughal United States 21 788 0.6× 888 1.0× 463 0.6× 353 0.5× 182 0.5× 115 1.7k
Steven Fruchtman United States 20 1.1k 0.8× 1.1k 1.2× 528 0.7× 408 0.5× 125 0.3× 71 1.8k
Michel Tulliez France 24 1.2k 0.9× 1.6k 1.7× 381 0.5× 789 1.1× 185 0.5× 74 2.4k
Roger J. Waltzman United States 12 1.2k 0.8× 1.0k 1.2× 658 0.8× 431 0.6× 96 0.3× 36 1.8k
Blanca Xicoy Spain 22 829 0.6× 1.0k 1.1× 436 0.5× 179 0.2× 605 1.6× 110 2.0k
Shuichi Miyawaki Japan 26 641 0.5× 2.0k 2.2× 864 1.1× 239 0.3× 191 0.5× 121 2.8k
Shin Fujisawa Japan 27 561 0.4× 1.1k 1.2× 380 0.5× 186 0.3× 410 1.1× 182 2.2k

Countries citing papers authored by Thomas Stauffer Larsen

Since Specialization
Citations

This map shows the geographic impact of Thomas Stauffer Larsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Stauffer Larsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Stauffer Larsen more than expected).

Fields of papers citing papers by Thomas Stauffer Larsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Stauffer Larsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Stauffer Larsen. The network helps show where Thomas Stauffer Larsen may publish in the future.

Co-authorship network of co-authors of Thomas Stauffer Larsen

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Stauffer Larsen. A scholar is included among the top collaborators of Thomas Stauffer Larsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Stauffer Larsen. Thomas Stauffer Larsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cédile, Oriane, Mads Thomassen, Michael Møller, et al.. (2025). Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non‐Hodgkin Large B‐Cell Lymphoma: A Comparative Study of Cell‐Free DNA and Formalin‐Fixed Paraffin‐Embedded Tissue. International Journal of Laboratory Hematology. 47(4). 669–679. 1 indexed citations
2.
Jensen, Paw, Peter de Nully Brown, Pär Josefsson, et al.. (2025). Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting. European Journal Of Haematology. 114(5). 832–839.
3.
Grantzau, Trine, Mia Dahl Sørensen, Michael Møller, et al.. (2025). Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies. PubMed. 2(3). 100096–100096.
4.
Hutchings, Martin, Anna Sureda, Francesc Bosch, et al.. (2025). Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. Journal of Clinical Oncology. 43(36). 3788–3798.
5.
Jelicic, Jelena, et al.. (2024). Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review. Critical Reviews in Oncology/Hematology. 196. 104293–104293. 2 indexed citations
6.
Brown, Peter de Nully, Matthew J. Maurer, Arushi Khurana, et al.. (2024). The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study. Leukemia & lymphoma. 65(14). 2173–2181. 2 indexed citations
7.
Brændstrup, Peter, Tarec Christoffer El‐Galaly, Michael Møller, et al.. (2024). Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022. Blood. 144(Supplement 1). 3099–3099.
8.
Duell, Johannes, Diana Alvarez Arias, Hilka Rauert‐Wunderlich, et al.. (2024). Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings. Blood. 144(Supplement 1). 2991–2991.
9.
Jakobsen, Lasse Hjort, Boris Modrau, Kristian Kragholm, et al.. (2023). Risk of dementia among older patients with lymphoma: A Danish nationwide matched cohort study. Journal of Geriatric Oncology. 15(1). 101672–101672. 2 indexed citations
10.
Jakobsen, Lasse Hjort, Kristian Kragholm, Joachim Bæch, et al.. (2023). Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study. Clinical Epidemiology. Volume 15. 337–348. 4 indexed citations
11.
Gerke, Oke, et al.. (2023). A retrospective head‐to‐head comparison of the Lugano classification and PERCIST for FDG‐PET/CT response assessment in diffuse large B‐cell lymphoma. Clinical Physiology and Functional Imaging. 44(1). 70–78. 3 indexed citations
12.
Bæch, Joachim, Simon Husby, Kristian Kragholm, et al.. (2023). Cardiovascular diseases after high‐dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population‐based study. British Journal of Haematology. 204(3). 967–975. 3 indexed citations
13.
Gradel, Kim Oren, Thomas Stauffer Larsen, Henrik Frederiksen, et al.. (2022). Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Annals of Medicine. 54(1). 713–722. 11 indexed citations
14.
Krejcik, Jakub, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, et al.. (2021). Harnessing the Immune System to Fight Multiple Myeloma. Cancers. 13(18). 4546–4546. 11 indexed citations
15.
Kjærgaard, Niels, et al.. (2018). What happens to urinary incontinence after pelvic organ prolapse surgery?. International Urogynecology Journal. 30(7). 1147–1152. 8 indexed citations
16.
Bak, Marie, Else Helene Ibfelt, Thomas Stauffer Larsen, et al.. (2016). The Danish National Chronic Myeloid Neoplasia Registry. Clinical Epidemiology. Volume 8. 567–572. 15 indexed citations
17.
Skov, Vibe, Mark Burton, Mads Thomassen, et al.. (2015). Supervised multi-classifier separation of the ph-negative myeloproliferative neoplasms. Haematologica. 100. 1 indexed citations
18.
Holmström, Morten Orebo, Klaus Kallenbach, Lasse Kjær, et al.. (2015). Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier. Ugeskrift for Læger. 177(26). 2–6. 2 indexed citations
19.
Beer, Philip, Christina A. Ortmann, Frank Stegelmann, et al.. (2010). Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica. 95(12). 2153–2156. 17 indexed citations
20.
Larsen, Thomas Stauffer, Niels Pallisgaard, Jacob Haaber Christensen, et al.. (2006). Nye molekylære markører ved de kroniske myeloproliferative sygdomme. I: PRV1-genet. Ugeskrift for Læger. 168(39). 3295–3299. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna L. Forrest Breakdown of academic impact, for papers by David Joske Breakdown of academic impact, for papers by Markus Pfirrmann Breakdown of academic impact, for papers by Tariq I. Mughal Breakdown of academic impact, for papers by Steven Fruchtman Breakdown of academic impact, for papers by Michel Tulliez Breakdown of academic impact, for papers by Roger J. Waltzman Breakdown of academic impact, for papers by Blanca Xicoy Breakdown of academic impact, for papers by Shuichi Miyawaki Breakdown of academic impact, for papers by Shin Fujisawa
Rankless by CCL
2026